Vivani Medical, Inc.

8-K · vani-20260604.htm iXBRL

0001266806 2026-06-04 2026-06-04
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

  
   FORM 8-K

  
 CURRENT REPORT
 Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
  
 Date of Report (Date of earliest event reported): June 4, 2026
  

  
 Vivani Medical, Inc.

 (Exact name of registrant as specified in its charter)
  
 Delaware

  
 001-36747

  
 02-0692322

 (State or other jurisdiction
 of incorporation)
  
 (Commission
 File Number)
  
 (IRS Employer
 Identification No.)

  
 1350 S. Loop Road

 Alameda ,   California
  
 94502

 (Address of principal executive offices)
 (Zip Code)

  
 Registrant’s telephone number, including area code: ( 415 )   506-8462
 N/A
 (Former name or former address, if changed since last report.)
  

  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  
 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  
 Securities registered pursuant to Section 12(b) of the Act:
  
 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which registered

 Common Stock, par value $0.0001 per share

  
 VANI

  
 The Nasdaq Capital Market

  
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  
 Emerging growth company ☐
  
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

 Item 7.01 . Regulation FD Disclosure.  
 Vivani Medical, Inc., or Vivani, will make a presentation at the Jefferies Global Healthcare Conference in New York on Thursday, June   4, 2026 at 11:05 a.m. Eastern. A copy of a slide presentation that Dr. Adam Mendelsohn, Vivani’s Chief Executive Officer intends to use during the conference is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. Vivani is also posting to the “Investors” portion of its website a copy of the slide presentation.   The slide presentation speaks only as of the date of this Current Report on Form 8-K. While Vivani may elect to update the slide presentation in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Vivani specifically disclaims any obligation to do so.
 The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.  
 Item 9.01. Financial Statements and Exhibits.  
 (d) Exhibits.              
 Exhibit No.
 Description

 99.1
  
 Vivani Medical, Inc. slide presentation dated June   4, 2026.

 104
  
 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  
  
  
 VIVANI MEDICAL, INC.

  
  
  

 Date: June   4, 2026
 By:
 /s/ Donald Dwyer

  
 Name:
 Donald Dwyer

  
 Title:
 Chief Business   Officer